Profile banner
Pavan Mallikarjun

Pavan Mallikarjun

Consultant psychiatrist, researcher and digital health co‑founder

England, United Kingdom
rocketreach+1
Joined March 2026
Favicon imageresearchgate.net
Favicon imagehome.lief.care

Network

369 connections
✨
Care Sector Founders
🏢
Corporate Legal Advisors
💰
Tax Finance Specialists
📈
Growth Equity Investors
💖
Lief Care Team
⚖️
Hill Dickinson Lawyers
⏰
Timeout Childrens Homes

Summary

Clinical early‑intervention psychiatrist with extensive NHS consultant experience in first‑episode psychosis services, combining frontline care with clinical leadership roles across multiple Birmingham trusts. trac+2
Active academic researcher focused on prediction models, stratified medicine and neurobiological phenotyping in psychosis and recent‑onset depression, contributing to algorithm development and multiple peer‑reviewed publications. nih+2
Digital health entrepreneur and director, co‑founding Lief to build care‑management technology for vulnerable children and care providers while maintaining clinical and academic roles. lief+1
Educator and course director involved in training and professional development (The Birmingham Course) and academic supervision at the University of Birmingham. theorg+1

Work

Education

Projects

Writing

Predicting treatment resistance from first-episode psychosis using routinely collected clinical information

January 1, 2023

Developed and externally validated models (MOZART and LASSO-based) to predict up-to-eight-year risk of clozapine use as a proxy for treatment-resistant schizophrenia using routinely collected clinical and blood biomarker data.

Favicon imagepubmed.ncbi.nlm.nih.gov

Using combined environmental–clinical classification models to predict role functioning outcome in clinical high‑risk states for psychosis and recent‑onset depression

February 1, 2022

Paper presenting combined environmental and clinical classification models to predict role functioning outcomes in clinical high‑risk states for psychosis and recent‑onset depression.

Favicon imagecambridge.org

Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC)

January 1, 2021

Describes the development and external validation of PsyMetRiC to predict up-to-six-year risk of metabolic syndrome in young people with psychosis using commonly recorded clinical data.

Favicon imageresearch.birmingham.ac.uk

The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication

January 1, 2016

A case-note review estimating 12-month relapse rates after antipsychotic discontinuation and identifying socio-demographic and clinical factors associated with relapse risk in a first-episode psychosis cohort.

Favicon imagepure-oai.bham.ac.uk